Sign In
Buy PHIO
$1.03
-0.0050 (-0.485%)
At Close: Jul 31, 2026
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
08:00am, Wednesday, 02'nd Oct 2024
Presentation and live Q&A to take place Wednesday, October 9, 2024, at 2 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - October 2, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical s
INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society
08:00am, Wednesday, 25'th Sep 2024
--Data will be presented at the conference in October in Montreal Marlborough, Massachusetts--(Newsfile Corp. - September 25, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotec
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
08:00am, Tuesday, 17'th Sep 2024
Presentation and live Q&A to take place Tuesday, September 24, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - September 17, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clini
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA
08:00am, Monday, 16'th Sep 2024
Phio's INTASYL self-delivering RNAi technology enhances cell potency and yield in Adoptive Cell Therapy Marlborough, Massachusetts--(Newsfile Corp. - September 16, 2024) - Phio Pharmaceuticals Corp. (
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
07:00am, Monday, 09'th Sep 2024
Conference to be held in New York City September 9-11th Marlborough, Massachusetts--(Newsfile Corp. - September 9, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology com
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
08:30am, Thursday, 29'th Aug 2024
Presentation and live Q&A to take place Thursday, September 5, 2024, at 12 PM EDT Marlborough, Massachusetts--(Newsfile Corp. - August 29, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical
Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
05:00pm, Wednesday, 14'th Aug 2024
Marlborough, Massachusetts--(Newsfile Corp. - August 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing tec
Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound
08:00am, Tuesday, 06'th Aug 2024
Phio's INTASYL compound targets aging skin disorders Marlborough, Massachusetts--(Newsfile Corp. - August 6, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company w
Phio Pharmaceuticals Announces New Chief Financial Officer
08:00am, Thursday, 01'st Aug 2024
Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing tech
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds
08:00am, Friday, 12'th Jul 2024
Marlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762
08:00am, Monday, 08'th Jul 2024
Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotech
Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds
08:00am, Friday, 05'th Jul 2024
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technol
Phio Pharmaceuticals Announces Reverse Stock Split
11:45am, Tuesday, 02'nd Jul 2024
Marlborough, Massachusetts--(Newsfile Corp. - July 2, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene s
Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging
07:30am, Tuesday, 18'th Jun 2024
Phio's Compound RXI-185 is designed to slow progression of UV induced collagen breakdown Marlborough, Massachusetts--(Newsfile Corp. - June 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a cli
Intratumoral PH-762 has encouraging safety profile in the initial cohort Escalation to proceed to next dose concentration Marlborough, Massachusetts--(Newsfile Corp. - May 28, 2024) - Phio Pharmaceuti
